National Drug Schedules

NOTE - Effective December 19, 2013, Schedule F to the Food and Drug Regulationswas repealed and replaced by a list of prescription drugs, called the Prescription Drug List. Therefore, all entries in the National Drug Schedules (NDS) whose footnote indicates that they appear in Schedule F (F1/F2) should now be considered part of the Prescription Drug List (PDL).

Entries whose footnote indicates that they are "Schedule F Recommended" (FR) should now be considered recommended for addition to the PDL. Some of the "Schedule F Recommended" entries may have been added or will shortly be added to the PDL by Health Canada, but either way these entries will continue to be listed in Schedule I of the NDS.

For more information on the Prescription Drug List, please consult the Health Canada website.

Drug Product Database
Licensed Natural Health Products Database

Print Friendly Export to CSV

Drug Name	Comment	Schedule	Date
Rabeprazole or its salts^PDL		I	DEC / 13
Rabies immune globulin		I	FEB / 02
Rabies vaccine		I	FEB / 02
Racemethionine		II	SEP / 98
Racemethorphan^N		I	JUN / 02
Racemoramide^N		I	JUN / 02
Racemorphan^N		I	JUN / 02
Raloxifene or its salts^PDL		I	DEC / 13
Raltegravir or its salts^PDL		I	DEC / 13
Raltitrexed or its salts or derivatives^PDL	including but not limited to raltitrexed disodium	I	DEC / 13
Ramipril or its salts or derivatives^PDL		I	DEC / 13
Ramucirumab^PDL		I	OCT / 15
Ranibizumab^PDL		I	DEC / 13
Ranitidine or its salts^PDL	except when sold in concentrations of 150 mg or less per oral dosage unit and indicated for the treatment of heartburn for human use	I	DEC / 13
Ranitidine or its salts.	when sold in concentrations of 150 mg or less per oral dosage unit and indicated for the treatment of heartburn, in package sizes containing more than 4,500 mg of ranitidine	III	MAR / 08
Ranitidine or its salts..	when sold in concentrations of 150 mg or less per oral dosage unit and indicated for the treatment of heartburn, in package sizes containing no more than 4,500 mg of ranitidine	U	FEB / 07
Rasagiline or its salts^PDL		I	DEC / 13
Rasburicase^PDL		I	DEC / 13
Raubasine or its salts^PDL		I	DEC / 13
Rauwolfia^PDL		I	DEC / 13
Regorafenib or its salts^PDL		I	DEC / 13
Remestemcel-L^PDL		I	DEC / 13
Remifentanil^N		I	JUN / 02
Remoxipride or its salts^PDL		I	DEC / 12
Repaglinide or its salts or derivatives^PDL		I	DEC / 13
Rescinnamine or its salts^PDL		I	DEC / 13
Reserpine or its salts^PDL	for human use	I	DEC / 13
Reslizumab^PDL		I	JUN / 17
Resocortol and its derivatives.^FR			AUG / 06
Resocortol or its derivatives^PDL		I	DEC / 13
Retapamulin^PDL		I	DEC / 13
Reviparin or its salts^PDL		I	DEC / 13
Rho D immune globulin		I	FEB / 02
Ribavirin^PDL		I	DEC / 13
Ribociclib or its salts^PDL		I	MAY / 18
Ricoiguat or its derivatives^PDL		I	DEC / 13
Rifabutin or its salts^PDL		I	DEC / 13
Rifampin or its salts or derivatives^PDL		I	DEC / 13
Rifaximin or its salts or derivatives^PDL		I	DEC / 13
Rilpivirine or its salts or derivatives^PDL	including but not limited to rilpivirine hydrochloride	I	DEC / 13
Riluzole or its salts^PDL		I	DEC / 13
Risankizumab^PDL		I	JUL / 19
Risedronic acid or its salts^PDL		I	DEC / 13
Risperidone or its salts^PDL		I	DEC / 13
Ritodrine and its salts^PDL		I	DEC / 13
Ritonavir^PDL		I	DEC / 13
Rituximab^PDL		I	DEC / 13
Rivaroxaban^PDL		I	DEC / 13
Rivastigmine or its salts^PDL		I	DEC / 13
Rizatriptan or its salts^PDL		I	DEC / 13
Rocuronium bromide^PDL		I	DEC / 13
Rofecoxib^PDL		I	DEC / 13
Roflumilast or its salts or derivatives^PDL		I	DEC / 13
Romidepsin^PDL		I	DEC / 13
Romifidine or its salts^PDL		I	DEC / 13
Romiplostim^PDL		I	DEC / 13
Ronidazole or its salts or derivatives^PDL	for human use	I	DEC / 13
Ropinirole or its salts^PDL		I	DEC / 13
Rose Bengal		II	SEP / 98
Rosiglitazone or its salts^PDL		I	DEC / 13
Rosoxacin or its salts^PDL		I	DEC / 13
Rosuvastatin or its salts^PDL		I	DEC / 13
Rotigotine or its salts or derivatives^PDL		I	DEC / 13
Rubella vaccine		II	DEC / 98
Rue and its preparations and extracts		II	SEP / 98
Rufinamide or its derivatives^PDL		I	DEC / 13
Rupatadine or its salts^PDL		I	FEB / 17
Ruxolitinib or its salts^PDL	including but not limited to ruxolitinib phosphate	I	DEC / 13

68 result(s)

Print Friendly Export to CSV

Footnotes

C1: Drug is in the Controlled Drugs and Substances Act and Part I of the Schedule to Part G of the Food and Drug Regulations
C2: Drug is in the Controlled Drugs and Substances Act and Part II of the Schedule to Part G of the Food and Drug Regulations
C3: Drug is in the Controlled Drugs and Substances Act and Part III of the Schedule to Part G of the Food and Drug Regulations
C4: drug is in the Controlled Drugs and Substances Act
C5: drug is in the Regulations Under CDSA
CR: drug has been recommended for addition to the Controlled Drugs and Substances Act
CR-C: drug has been recommended for addition to the Controlled Drugs and Substances Act, Part G of the Food and Drug Regulations
CR-N: drug has been recommend for addition to the Controlled Drugs and Substances Act, Narcotic Control Regulations
CR-TS: drug has been recommended for addition to the Controlled Drugs and Substances Act, Benzodiazepines and Other Targeted Substances Regulations
F1: drug appears in Part I of Schedule F to the Food and Drugs Act and Regulations
F2: drug appears in Part II of Schedule F to the Food and Drugs Act and Regulations
FR: drug has been recommended for addition to Schedule F to the Food and Drugs Act and Regulations ("Schedule F Recommended")
N: drug is in the Narcotic Control Regulations under the Controlled Drugs and Substances Act
NR: drug has not been reviewed by NDSAC
PDL: drug is in the Prescription Drug List (effective Dec. 19, 2013)
R: drug is in Part J of the Food and Drugs Act and listed in the Controlled Drugs and Substances Act
TS: drug is in the Benzodiazepines and Other Targeted Substances Regulations under the Controlled Drugs and Substances Act
U: drug has been reviewed by NDSAC and is unscheduled

National Drug Schedules

Search: National Drug Schedules

68 result(s)

Footnotes